An NCI-designated Comprehensive Cancer Center
Vu Nguyen Ngo

Vu Nguyen Ngo, Ph.D.

Associate Research Professor, Department of Systems Biology
Research Focus
  • Molecular pathogenesis of lymphoid malignancies

Research Teams

  • Systems Biology
Cancer cells are often addicted to a transformed state that involves multiple signal transduction pathways. A major goal of Dr. Ngo’s research is to discover abnormal signaling that make cancer more aggressive and resistant to therapy. By combining high throughput genetic screen and next-generation sequencing approaches, he has identified key pathways and important molecular targets that are critical for cancer cell proliferation and survival (Ngo VN et al. 2011, Nature). His research has also led to discovery of cancer gene mutations that cause treatment resistance (Mohanty A et al. 2016, Oncotarget).

Dr. Ngo’s laboratory in the Department of Systems Biology will focus on genetic and epigenetic mechanisms of cancer mutations and their interactions in driving tumor development. His laboratory will employ large-scale functional genetic screens using RNA interference technology in combination with genomics and proteomics approaches to dissect disease mechanisms in lymphoid malignancies. He also has a special focus on developing animal tumor models for aggressive lymphomas including mantle cell lymphoma.

Dr. Ngo completed his B.A. degree from the University of California, Berkeley and earned a Ph.D. in biomedical sciences from the University of California, San Francisco. His postdoctoral training was with Dr. Louis M. Staudt at the National Cancer Institute, National Institute of Health, Bethesda. Prior to joining the Department of Systems Biology, he was an assistant professor in the Division of Stem Cell and Leukemia Research at City of Hope.
  • Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2018 Dec 10. doi: 10.1182/blood-2018-05-851667. [Epub ahead of print].
  • Mohanty S, Mohanty A, Sandoval N, Tran T, Bedell V, Wu J, Scuto A, Murata-Collins J, Weisenburger DD, Ngo VN. Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leukemia & Lymphoma. 2017; 58(3): 676-688.
  • Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016; 7(45):73558-73572.
  • Ngo VN. Identification of pathogenetically relevant genes in lymphomagenesis by shRNA library screens. Methods Mol Biol. 2013; 971:245-63.
  • Ngo VN, Young R, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically Active MYD88 Mutations in Human Lymphoma. Nature. 2011; 470 (7332): 115-9.
  • Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, et al.  A Loss-of-function RNA Interference Screen for Molecular Targets in Cancer. Nature. 2006; 441 (7089): 106-10.

View all publications

In The News